Illumina (NASDAQ:ILMN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research note released on Sunday,Wall Street Zen reports.

A number of other analysts have also weighed in on the company. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the company from $135.00 to $260.00 in a research note on Wednesday, September 9th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Canaccord Genuity Group boosted their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research note on Monday, August 3rd. Finally, Guggenheim boosted their target price on Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $225.94.

Illumina Price Performance

Shares of Illumina stock opened at $271.17 on Friday. The business has a 50 day simple moving average of $230.11 and a two-hundred day simple moving average of $183.38. Illumina has a 12 month low of $88.00 and a 12 month high of $309.35. The stock has a market capitalization of $40.95 billion, a P/E ratio of 53.72, a PEG ratio of 3.92 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts predict that Illumina will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $3,374,423,000. Primecap Management Co. CA acquired a new stake in shares of Illumina during the 2nd quarter worth $617,981,000. Jupiter Topco LLC acquired a new stake in shares of Illumina during the 2nd quarter worth $358,652,000. WCM Investment Management LLC increased its holdings in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Illumina in the 2nd quarter worth $293,846,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s new SpliceAI2 genomic model is drawing attention because it could strengthen the company’s clinical-genomics narrative and expand the potential applications of its sequencing data and AI tools. Investors may view the launch as evidence that Illumina is moving beyond instruments and consumables toward higher-value software and clinical insights. Did Illumina’s New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative?
• Positive Sentiment: Analysts expect Illumina’s sequencing business to continue recovering, supported by improving demand and recent AI developments. The company’s latest reported quarter exceeded consensus revenue and earnings estimates, while full-year 2026 EPS guidance remains $5.30–$5.40. Illumina’s Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?
• Neutral Sentiment: Illumina entered a new dealer agreement intended to support financing. The arrangement may help sales execution or customer purchasing, but the available announcement provides limited detail on its expected financial impact. Illumina Establishes New Dealer Agreement to Support Financing
• Negative Sentiment: Illumina has initiated a voluntary global Class II recall involving certain NovaSeq 6000Dx and NextSeq 550Dx diagnostic systems. Approximately 80 units are affected because of a security vulnerability in associated DRAGEN servers. The issue reportedly concerns server configuration rather than sequencing accuracy or core hardware, limiting the direct product-risk implications but still creating remediation, customer-confidence and compliance concerns. Illumina Starts Global Recall of Diagnostic Sequencers Over Security Vulnerability
• Negative Sentiment: After a roughly 191% one-year rally, valuation-focused commentary suggests ILMN may be near fair value, leaving less room for execution mistakes. Investors are increasingly demanding that the sequencing recovery and AI push translate into sustained cash-flow growth, while upcoming third-quarter results could become a near-term catalyst. Illumina Stock May Be About Fair Value After Genomics AI Launch

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.